The ECE1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HeLa epithelial cell line with targeted disruption of the ECE1 gene. This loss-of-function model abolishes the enzymatic conversion of big endothelin-1 to the mature vasoactive peptide endothelin-1 (EDN1), thereby interrupting downstream signaling cascades mediated by endothelin receptors. The polyclonal knockout format provides a genetically heterogeneous population, suitable for functional studies examining ECE1-dependent processes in cancer and cardiovascular research.
HeLa cells are an immortalized human cervical adenocarcinoma line positive for HPV18, widely employed as a model epithelial cancer cell system. They are characterized by robust proliferation, high transfectability, and well-characterized signaling networks, making them a standard host for CRISPR-based gene editing applications. The ECE1 knockout HeLa polyclonal population retains this malignant background while enabling the dissection of ECE1-specific functions in a cancer-relevant context.
ECE1 encodes endothelin-converting enzyme-1, a membrane-bound metalloprotease that catalyzes the critical final step in the biosynthesis of endothelin-1, a potent vasoconstrictor and mitogen. ECE1 transcription is activated by upstream signals including TNF-alpha, IL-1beta, hypoxia, and shear stress, through AP-1 and NF-kB transcription factors. The mature EDN1 peptide binds to G protein-coupled endothelin receptors EDNRA and EDNRB, initiating Gq/11-mediated activation of phospholipase C (PLC), which generates inositol trisphosphate (IP3) and diacylglycerol (DAG) to release intracellular calcium. Concurrently, EDN1 stimulates the Ras-Raf-MEK-ERK cascade, promoting cell proliferation, and the PI3K/Akt pathway, enhancing survival. ECE1 additionally processes other vasoactive peptides such as bradykinin and substance P, integrating with broader proteolytic signaling networks.
Disruption of ECE1 in HeLa cells abolishes endothelin-1 production, thereby uncoupling autocrine/paracrine signaling through EDNRA and EDNRB. This loss attenuates downstream ERK phosphorylation and calcium mobilization, which are essential for HeLa cell proliferation and survival. Since HeLa cells express functional endothelin receptors and exhibit basal endothelin system activity, the knockout model provides a clean background to evaluate the specific contribution of ECE1 to cancer cell growth, invasion, and apoptosis resistance. It also permits discrimination between endothelin-dependent and independent effects of upstream regulators like TNF-alpha and hypoxia.
The ECE1 Knockout HeLa Polyclonal Cells are suited for a broad range of functional investigations, including the dissection of endothelin signaling in cancer biology, validation of ECE1 inhibitors, and analysis of vasoactive peptide processing. Typical downstream assays include Western blotting to monitor EDN1 maturation, RT-qPCR for EDN1 expression, immunofluorescence for ECE1 localization, and MTT assays to measure proliferation effects. Calcium imaging and phospho-ERK Western blotting allow quantitative evaluation of signaling output, while migration and invasion assays probe metastatic potential. This polyclonal knockout population provides a cost-effective platform for initial drug screening and pathway epistasis experiments. For further information, please contact Ascent Research.
